المؤلفون: Jussara Hagen, Timothy Ginader, Abbey L. Perl, Terry A. Braun, Gideon K. D. Zamba, Bart J. Brown, Dawn E. Quelle, James R. Howe, Jacqueline A. Reilly, Goutham Narla, Benjamin W. Darbro, Fenghuang Zhan, Angela M. Schab, Aaron T. Scott, Blake L. Letney, Jordan L. Kohlmeyer, Courtney A. Kaemmer, Shaikamjad Umesalma, Joseph S. Dillon, David K. Meyerholz, Mariah R. Leidinger, Stefan Strack, Thomas M. O'Dorisio, Andrew M. Bellizzi, Agshin F. Taghiyev, Frederick W. Quelle, Nitija Tiwari, Ronald A. Merrill, Ryan M. Sheehy

المصدر: Journal of Clinical Investigation. 129:1641-1653

مصطلحات موضوعية: 0301 basic medicine, Enzyme Activators, macromolecular substances, Neuroendocrine tumors, environment and public health, law.invention, 03 medical and health sciences, 0302 clinical medicine, law, Cell Line, Tumor, medicine, Humans, Gene silencing, Protein Phosphatase 2, Protein kinase B, PI3K/AKT/mTOR pathway, Oncogene Proteins, Chemistry, Activator (genetics), TOR Serine-Threonine Kinases, Tumor Suppressor Proteins, G1 Phase, General Medicine, Protein phosphatase 2, medicine.disease, Carcinoma, Neuroendocrine, Pancreatic Neoplasms, enzymes and coenzymes (carbohydrates), 030104 developmental biology, rab GTP-Binding Proteins, 030220 oncology & carcinogenesis, Cancer research, Phosphorylation, Suppressor, Proto-Oncogene Proteins c-akt, Signal Transduction, Research Article

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::232bebbf58142beac4d6bf84a1f8bff8
https://doi.org/10.1172/jci123049